NO961865L - Piperidiner, pyrrolidiner og heksahydro-1H-azepiner fremmer frigjörelse av veksthormon - Google Patents

Piperidiner, pyrrolidiner og heksahydro-1H-azepiner fremmer frigjörelse av veksthormon

Info

Publication number
NO961865L
NO961865L NO961865A NO961865A NO961865L NO 961865 L NO961865 L NO 961865L NO 961865 A NO961865 A NO 961865A NO 961865 A NO961865 A NO 961865A NO 961865 L NO961865 L NO 961865L
Authority
NO
Norway
Prior art keywords
growth hormone
hexahydro
compounds
azepines
pyrrolidines
Prior art date
Application number
NO961865A
Other languages
English (en)
Other versions
NO961865D0 (no
Inventor
Gregori J Morriello
Arthur A Patchett
Lihu Yang
Meng H Chen
Ravi Nargund
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/323,988 external-priority patent/US5492916A/en
Priority claimed from US08/323,998 external-priority patent/US5492920A/en
Priority claimed from US08/323,994 external-priority patent/US5494919A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO961865D0 publication Critical patent/NO961865D0/no
Publication of NO961865L publication Critical patent/NO961865L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Foreliggende oppfinnelse er rettet mot visse piperidin-, pyrrolidin- og heksahydro-lH-azepinforbindel- i ser med generell strukturformel (I) H H O R, l l II .'« R,¿p-N-C-A-N o=n R* på veksthormon, og til å behandle medi- sinske tilstander som forbedres ved hjelp av de anabolske effektene av veksthormon. Veksthormonfrigjørende preparater som inneholder slike forbin- | deiser som den aktive bestanddel derav, '. er også beskrevet. C=O (I) 3 hvor Rlr R3, R4, R5, A, W, X, Y og n er som definert i krav 1. Disse forbindel- ' sene fremmer frigjørelsen av veksthor- mon hos mennesker og dyr. Denne egen- skapen kan benyttes til å fremme veksten av matdyr for å gjøre produk- sjonen av spiselige kjøttprodukter mer effektiv, og hos mennesker til å be- ! handle fysiologiske eller medisinske tilstander som er kjennetegnet ved en svikt i veksthormonutskillelse, slik som lav legemshøyde hos barn med mangel
NO961865A 1993-11-09 1996-05-08 Piperidiner, pyrrolidiner og heksahydro-1H-azepiner fremmer frigjörelse av veksthormon NO961865L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14944193A 1993-11-09 1993-11-09
US16514993A 1993-12-10 1993-12-10
US17344993A 1993-12-23 1993-12-23
US08/323,988 US5492916A (en) 1993-12-23 1994-10-17 Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US08/323,998 US5492920A (en) 1993-12-10 1994-10-17 Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US08/323,994 US5494919A (en) 1993-11-09 1994-10-17 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
PCT/US1994/012816 WO1995013069A1 (en) 1993-11-09 1994-11-07 Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone

Publications (2)

Publication Number Publication Date
NO961865D0 NO961865D0 (no) 1996-05-08
NO961865L true NO961865L (no) 1996-07-08

Family

ID=27558364

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961865A NO961865L (no) 1993-11-09 1996-05-08 Piperidiner, pyrrolidiner og heksahydro-1H-azepiner fremmer frigjörelse av veksthormon

Country Status (16)

Country Link
EP (1) EP0739204A4 (no)
JP (1) JPH10506091A (no)
KR (1) KR960705808A (no)
CN (1) CN1174504A (no)
AU (1) AU1172995A (no)
BG (1) BG100555A (no)
BR (1) BR9408019A (no)
CA (1) CA2175218A1 (no)
CZ (1) CZ134296A3 (no)
FI (1) FI961951A0 (no)
HU (1) HUT74733A (no)
LV (1) LV11525B (no)
NO (1) NO961865L (no)
PL (1) PL322706A1 (no)
SK (1) SK56296A3 (no)
WO (1) WO1995013069A1 (no)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5767118A (en) * 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996035713A1 (en) * 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
US5620993A (en) * 1995-06-07 1997-04-15 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AU7445498A (en) 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
DK1077941T3 (da) * 1998-05-11 2009-12-07 Novo Nordisk As Forbindelser med væksthormonfrigörende egenskaber
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
DZ2815A1 (fr) * 1998-06-12 2003-12-01 Smithkline Beecham Corp Inhibiteurs de protéase.
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
EP1097170A1 (en) 1998-07-13 2001-05-09 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
WO2000009538A2 (en) 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor
EP1159292A2 (en) 1998-08-14 2001-12-05 Administrators of The Tulane Educational Fund Compounds having growth hormone releasing activity
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
JP2002523368A (ja) * 1999-02-19 2002-07-30 イーライ・リリー・アンド・カンパニー 成長ホルモン分泌促進薬
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
JP2002539192A (ja) * 1999-03-15 2002-11-19 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ阻害剤としての新規な化合物及び組成物
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6784200B2 (en) 2000-10-13 2004-08-31 Bristol-Myers Squibb Pharma Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
CA2384240A1 (en) 1999-10-15 2001-04-26 Dean A. Wacker Benzylcycloalkyl amines as modulators of chemokine receptor activity
US6586446B1 (en) 1999-10-15 2003-07-01 Bristol-Myers Squibb Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
ATE310728T1 (de) * 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
WO2001098268A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
MXPA03005601A (es) 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
CN1324008C (zh) 2001-09-14 2007-07-04 安万特药物公司 作为组织蛋白酶抑制剂的新化合物和组合物
WO2003024401A2 (en) 2001-09-18 2003-03-27 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
DE60222286T2 (de) * 2001-09-27 2008-06-19 Laboratoires Serono S.A., Coinsins Verfahren zur erhöhung des testosteronspiegels
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2003042197A1 (en) 2001-11-14 2003-05-22 Aventis Pharmaceuticals Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
US7153822B2 (en) 2002-01-29 2006-12-26 Wyeth Compositions and methods for modulating connexin hemichannels
TW200409630A (en) 2002-09-12 2004-06-16 Bristol Myers Squibb Co N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR101324340B1 (ko) * 2004-06-29 2013-10-31 헬신 세라퓨틱스 (유.에스.) 인크. (3ｒ)-1-(2-메틸알라닐-ｄ-트립토필)-3-(페닐메틸)-3-피페리딘카르복실산 1,2,2-트리메틸하이드라지드의 결정 형태
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
PT1966130E (pt) 2005-12-23 2014-01-30 Zealand Pharma As Compostos miméticos de lisina modificados
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP1897956A1 (en) 2006-09-06 2008-03-12 Lonza AG Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase
DK2468724T3 (en) 2006-12-21 2016-02-22 Zealand Pharma As Synthesis of pyrrolidine compounds
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2016021191A1 (en) * 2014-08-05 2016-02-11 Raqualia Pharma Inc. Serine derivatives as ghrelin receptor agonists
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
HU231150B1 (hu) 2017-03-13 2021-03-29 Richter Gedeon Nyrt Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom
AU2019223014B2 (en) 2018-02-21 2024-10-17 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US10640467B2 (en) * 2018-06-01 2020-05-05 Theravance Biopharma R&D Ip, Llc Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
CN114805305B (zh) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 一种化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
HU180925B (en) * 1979-06-28 1983-05-30 Richter Gedeon Vegyeszet Process for producing tripeptide-amides trh-analogues,effectives on the central nerve systhem
GB8332704D0 (en) * 1983-12-07 1984-01-11 Pfizer Ltd Growth promotants for animals
US5036045A (en) * 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4782139A (en) * 1985-10-28 1988-11-01 Eli Lilly And Company Selective chemical removal of a protein amino-terminal residue
US4997825A (en) * 1986-12-22 1991-03-05 Eli Lilly And Company Synergistic treatment method
US5162302A (en) * 1988-03-18 1992-11-10 University Of Delaware Endocrine manipulation to improve body composition of poultry
US5084442A (en) * 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) * 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
IE912345A1 (en) * 1990-08-03 1992-02-12 Pharmacia Ab Treatment of human lactation failure
EP0559751B1 (en) * 1990-11-26 1997-03-26 RECKER, Robert R. Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
JP3098082B2 (ja) * 1991-12-12 2000-10-10 三井化学株式会社 アミノ基含有化合物の製造方法
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Also Published As

Publication number Publication date
FI961951A (fi) 1996-05-08
HUT74733A (en) 1997-02-28
HU9601230D0 (en) 1996-07-29
LV11525A (lv) 1996-10-20
PL322706A1 (en) 1998-02-16
NO961865D0 (no) 1996-05-08
CN1174504A (zh) 1998-02-25
FI961951A0 (fi) 1996-05-08
EP0739204A1 (en) 1996-10-30
LV11525B (en) 1997-02-20
AU1172995A (en) 1995-05-29
BG100555A (bg) 1996-10-31
CZ134296A3 (en) 1996-12-11
WO1995013069A1 (en) 1995-05-18
KR960705808A (ko) 1996-11-08
EP0739204A4 (en) 2000-03-15
SK56296A3 (en) 1997-02-05
JPH10506091A (ja) 1998-06-16
CA2175218A1 (en) 1995-05-18
BR9408019A (pt) 1997-08-26

Similar Documents

Publication Publication Date Title
NO961865L (no) Piperidiner, pyrrolidiner og heksahydro-1H-azepiner fremmer frigjörelse av veksthormon
NO952294L (no) Spiropiperidiner og homologer aktiverer frigivelse av veksthormon
AU5232093A (en) Spiro piperidines and homologs which promote release of growth hormone
HU9200915D0 (en) Process for the production of new benzole-ring condensed lactames and of medical preparations containing them as active agents
DK254787D0 (da) Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel
NO931133D0 (no) Legemidler av polyhydroksymetylenderivater, fremgangsmaater for deres fremstilling og anvendelse
GR3005398T3 (no)
AU5232193A (en) Spiro piperidines and homologs promote release of growth hormone
SE8802673L (sv) Anti-denatureringsmedel foer aetliga pastaprodukter
AU4519189A (en) Medicaments for the treatment of toxoplasmosis
IL85031A (en) Lyophilized aspoxicillin preparation and its manufacture
HU9201295D0 (en) Medical preparations for treating cryptosporidiosys
RU93052807A (ru) Лекарственное средство с антигиперкератической активностью
RU93053982A (ru) Мазь для лечения открытых ран